treatment

R. Coleman Lindsley, MD, PhD

Institution
Hematology and Oncology Dana-Farber Cancer Institute
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Robert Coleman Lindsley, M.D., PhD. is a physician scientist at Dana-Farber Cancer Institute, specializing in research topics associated with MDS. His career has developed in conjunction with his interest in how disease evolves, and in turn, how new and existing therapies can interrupt the process of disease progression. The clinical research focus he has chosen in addressing problems with MDS has led to work in two important areas; examining how the fundamental properties of MDS change over time, and the features of MDS that cause resistance to therapy. Dr. Lindsley’s efforts include

Erica Warlick, MD

Institution
Health Tree Foundation
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)

Pamela Becker, MD, PhD

Institution
City of Hope
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
About
Dr. Becker is pursuing several areas of research investigation, including 1) the mechanism of adhesion mediated chemotherapy resistance in acute myeloid leukemia and 2) hematopoietic stem cell gene transfer for a genetic disorder of DNA repair, Fanconi anemia. TODO: Above paragraph was copied from online profile, may need to be edited.

Mikkael Sekeres, MD, MS

Institution
Sylvester Comprehensive Cancer Center and University of Miami
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
About
Mikkael A. Sekeres, MD, MS has been Medical Advisory Board Co-Chair since 2004. He is currently the Physician Liaison in Hematology and Chief of the Division of Hematology at the Sylvester Comprehensive Center at the University. Previously, Dr. Sekeres was the professor of medicine, director of the leukemia program, and Vice Chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute in Ohio. He earned his medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine. Dr. Sekeres completed his postgraduate training at

Richard M. Stone, MD

Institution
Dana-Farber Cancer Institute
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Stone received his MD in 1981 from Harvard Medical School, his internal medicine residency training at Brigham and Women's Hospital, and his hematology-oncology fellowship at DFCI. He has performed numerous laboratory and clinical studies on acute leukemia and related disorders, and frequently participates in grand rounds worldwide. He is currently the Director of the Adult Acute Leukemia Program at DFCI, serves on the Medical Oncology Board of the American Board of Internal Medicine, and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and

How do I get my medical records from a doctor?

If you want a copy of your medical records, you  must submit a written request to the hospital or the doctor's office. The law requires that patients provide doctors with written authorization to disclose medical records or the information contained in them. Some hospitals have their own form that needs to be completed. Patients may receive copies of their medical records, however the originals must remain in the physician's or hospital's file.  Please consult with your physician's office for access to digital records.

How do I decide between antithymocyte globulin (ATG) and bone marrow transplant for treatment of aplastic anemia?

This is an individual decision and should be discussed in detail with your doctor and the medical team that would be involved in either treatment approach. They can help you understand your specific risks and potential benefits of these options.

The main goal of aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood cells, white blood cells, and platelets. The term aplastic is a Greek word meaning not to form. Anemia is a condition that happens when red blood cell count is low. Most… treatment is to increase the number of healthy cells in your blood so you will feel better, no longer need transfusions and have improved quality of life.

Immunosuppressive therapy: Immunosuppressive drug therapy lowers your body's immune response. This prevents your immune system from attacking your bone marrow, allowing bone marrow stem cells to grow, which raises blood counts. For older patients with acquired aplastic anemia, immunosuppressive drug therapy is the… using ATG and cyclosporine: Cyclosporine is used along with antithymocyte globulin (ATG), another immunosuppressant, for treating aplastic anemia and some other forms of bone marrow failure. works by preventing your immune system from attacking your bone marrow: The soft, spongy tissue inside most bones. Blood cells are formed in the bone marrow. , letting your stem cells: Cells in the body that develop into other cells. There are two main sources of stem cells. Embryonic stem cells come from human embryos and are used in medical research. Adult stem cells in the body repair and maintain the organ or tissue in which they are found. Blood-forming (hemapoietic) stem… grow back and raising your blood count. This is a standard treatment for older patients or those without a stem cell donor.

Stem cell transplantation involves putting blood-forming stem cells from a healthy donor into your bloodstream. These cells travel to your bone marrow and start making healthy cells. This is a standard treatment for younger patients with severe aplastic anemia (SAA) and other bone marrow failure: A condition that occurs when the bone marrow stops making enough healthy blood cells. The most common of these rare diseases are aplastic anemia, myelodysplastic syndromes (MDS) and paroxysmal nocturnal hemoglobinuria (PNH). Bone marrow failure can be acquired (begin any time in life) or can be… diseases if a donor is not available.

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.